Companies
TellmeGen
a clinical-grade DTC platform offering the TellmeGen Advanced panel (around EUR 149) and the Ultra 30x WGS test that analyzes the full genome for common and rare disease risk, with pharmacogenomic drug-response reporting under IVDR.
- Country
- Spain
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $271,010 (debt financing) | caplight.com |
| Headcount | 37 employees (as of March 2026) | caplight.com |
| Production site | Denmark and Spain | shop.tellmegen.com · tellmegen.com |
| Certification | ISO 9001, ISO 17025, ISO 13485, ISO 15189, GLP, GCP, cGMP | en.dna-story.com · shop.tellmegen.com · tellmegen.com |
| Regulatory approval | Authorization nº 11540 (Conselleria de Sanidad de la Generalitat Valenciana) | shop.tellmegen.com |
| Capacity | High volume of samples processed monthly in collaboration with Eurofins Genomics Denmark medium confidence | tellmegen.com |
Independent sources: caplight.com · en.dna-story.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| DTC genetic testing | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.